Prediction of Axillary Nodal Status according to the Axillary Lymph Node to Primary Breast Tumor Maximum Standardized Uptake Value Ratio on 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose: This study aimed to evaluate the usefulness of the axillary lymph node to primary breast tumor maximum standardized uptake value (SUVmax) ratio in 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for predicting the presence of metastasis in axillary lymph nodes. Methods: Herein, 196 consecutive patients with breast cancer who underwent PET/CT before surgery from January 2009 to January 2013 were included. We calculated the axillary lymph node to primary breast tumor SUVmax ratio using PET/CT. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the ratio were compared with those of nodal SUVmax and axillary ultrasonography. Axillary node metastasis was confirmed with sentinel node biopsy or axillary dissection. Results: The SUVmax ratio (cutoff, 0.14; area under the curve, 0.741) had 55.4% sensitivity, 91.6% specificity, 76.6% PPV, and 80.5% NPV for predicting axillary node metastasis. No significant difference was observed in terms of predicting axillary node metastasis among the SUVmax ratio, nodal SUVmax, and ultrasonography. In the multivariate analysis, primary tumor size (p=0.014), SUVmax of the primary tumor (p=0.011), axillary ultrasonography findings, nodal SUVmax, and SUVmax ratio were significantly associated with lymph node metastasis (p<0.001). Conclusion: The axillary lymph node to primary breast tumor SUVmax ratio predicted axillary lymph node metastasis, although no significant difference in diagnostic performance was observed between PET/CT and ultrasonography. The axillary lymph node to primary breast tumor SUVmax ratio may be considered an additional method for the preoperative evaluation of axillary lymph node status.
Abstract
Purpose: This study aimed to evaluate the usefulness of the axillary lymph node to primary breast tumor maximum standardized uptake value (SUVmax) ratio in 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) for predicting the presence of metastasis in axillary lymph nodes. Methods: Herein, 196 consecutive patients with breast cancer who underwent PET/CT before surgery from January 2009 to January 2013 were included. We calculated the axillary lymph node to primary breast tumor SUVmax ratio using PET/CT. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the ratio were compared with those of nodal SUVmax and axillary ultrasonography. Axillary node metastasis was confirmed with sentinel node biopsy or axillary dissection. Results: The SUVmax ratio (cutoff, 0.14; area under the curve, 0.741) had 55.4% sensitivity, 91.6% specificity, 76.6% PPV, and 80.5% NPV for predicting axillary node metastasis. No significant difference was observed in terms of predicting axillary node metastasis among the SUVmax ratio, nodal SUVmax, and ultrasonography. In the multivariate analysis, primary tumor size (p=0.014), SUVmax of the primary tumor (p=0.011), axillary ultrasonography findings, nodal SUVmax, and SUVmax ratio were significantly associated with lymph node metastasis (p<0.001). Conclusion: The axillary lymph node to primary breast tumor SUVmax ratio predicted axillary lymph node metastasis, although no significant difference in diagnostic performance was observed between PET/CT and ultrasonography. The axillary lymph node to primary breast tumor SUVmax ratio may be considered an additional method for the preoperative evaluation of axillary lymph node status.
참고문헌 (27)
- Jemal A, "Cancer statistics, 2008", CA Cancer J Clin, 58, pp.71~96 (2008)
- Chua B, "Frequency and predictors of axillary lymph node metastases in invasive breast cancer", ANZ J Surg, 71, pp.723~728 (2001)
- Ivens D, "Assessment of morbidity from complete axillary dissection", Br J Cancer, 66, pp.136~138 (1992)
- Lyman GH, "American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer", J Clin Oncol, 23, pp.7703~7720 (2005)
- fluorodeoxyglucose positron emission tomography, "computed tomography compared with conventional imaging procedures", J Clin Oncol, 26, pp.4746~4751 (2008)
- Veronesi U, "A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases", Ann Oncol, 18, pp.473~478 (2007)
- Heusner TA, "Diagnostic value of full-dose FDG PET", CT for axillary lymph node staging in breast cancer patients, 2009, pp.36, 1543~1550
- Quon A, "FDG-PET and beyond: molecular breast cancer imaging", J Clin Oncol, 23, pp.1664~1673 (2005)
- Kim J, "Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET", CT scan in early breast cancer patients: single institutional experience, 2009, pp.33, 943~949
- Carkaci S, "Semiquantitative analysis of maximum standardized uptake values of regional lymph nodes in inflammatory breast cancer: is there a reliable threshold for differentiating benign from malignant?", Acad Radiol, 19, pp.535~541 (2012)
- Lovrics PJ, "A prospective evaluation of positron emission tomography scanning, sentinel lymph node biopsy, and standard axillary dissection for axillary staging in patients with early stage breast cancer", Ann Surg Oncol, 11, pp.846~853 (2004)
- Ahn JH, "The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer", Acta Radiol, 51, pp.859~865 (2010)
- Duchesne N, "Redefining ultrasound appearance criteria of positive axillary lymph nodes", Can Assoc Radiol J, 56, pp.289~296 (2005)
- Gil-Rendo A, "Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer", Br J Surg, 93, pp.707~712 (2006)
- Straver ME, "Feasibility of FDG PET", CT to monitor the response of axillary lymph node metastases to neoadjuvant chemotherapy in breast cancer patients, 2010, pp.37, 1069~1076
- Soret M, "Partial-volume effect in PET tumor imaging", J Nucl Med, 48, pp.932~945 (2007)
- Barranger E, "Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer", Ann Surg Oncol, 10, pp.622~627 (2003)
- Hodgson NC, "Is there a role for positron emission tomography in breast cancer staging?", J Clin Oncol, 26, pp.712~720 (2008)
- fluorodeoxyglucose uptake by the primary tumor a prognostic factor in breast cancer?, "Breast", 2013, 39~43
- Basu S, "Comparison of triple-negative and estrogen receptor-positive", progesterone receptor-positive, positron emission tomography imaging parameters: a potentially useful method for disease characterization, pp.Cancer, 2008[DOI]
- Sanli Y, "Increased FDG uptake in breast cancer is associated with prognostic factors", Ann Nucl Med, 26, pp.345~350 (2012)
- Hahn S, "Diagnostic accuracy of dual-time-point 18F-FDG PET", CT for the detection of axillary lymph node metastases in breast cancer patients, 2012, pp.53, 518~523
- fluorodeoxyglucose positron emission tomography standardized uptake value of neck lymph nodes predicts neck cancer control and survival rates in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes, "Int J Radiat Oncol Biol Phys", 2009, 1054~1061
- Kidd EA, "Pelvic lymph node F-18 fluorodeoxyglucose uptake as a prognostic biomarker in newly diagnosed patients with locally advanced cervical cancer", Cancer, 116, pp.1469~1475 (2010)
- 2-Deoxy-2-fluoro-D-glucose-positron emission tomography, "J Cancer Res Clin Oncol", 2004, 273~278
- Song BI, "18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET", CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer, 2012, pp.53, 1337~1344
- Zornoza G, "18F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer", Eur J Surg Oncol, 30, pp.15~19 (2004)